Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) has entered into an agreements with Chromo Laboratories India Private Limited for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit (CR Bio), for a consideration of Rs. 16 crore.

The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations.